PT2413913T - Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar - Google Patents
Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os prepararInfo
- Publication number
- PT2413913T PT2413913T PT107143869T PT10714386T PT2413913T PT 2413913 T PT2413913 T PT 2413913T PT 107143869 T PT107143869 T PT 107143869T PT 10714386 T PT10714386 T PT 10714386T PT 2413913 T PT2413913 T PT 2413913T
- Authority
- PT
- Portugal
- Prior art keywords
- making
- methods
- same
- pharmaceutical formulations
- nitrocatechol derivatives
- Prior art date
Links
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical class OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16579409P | 2009-04-01 | 2009-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2413913T true PT2413913T (pt) | 2022-06-09 |
Family
ID=42229943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107143869T PT2413913T (pt) | 2009-04-01 | 2010-03-31 | Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100256194A1 (enExample) |
| EP (1) | EP2413913B1 (enExample) |
| JP (2) | JP5864410B2 (enExample) |
| KR (1) | KR101824257B1 (enExample) |
| CN (2) | CN102438595B (enExample) |
| AU (1) | AU2010231962B2 (enExample) |
| BR (1) | BRPI1016132B8 (enExample) |
| CA (1) | CA2757418C (enExample) |
| DK (1) | DK2413913T3 (enExample) |
| ES (1) | ES2915698T3 (enExample) |
| MX (1) | MX361618B (enExample) |
| PL (1) | PL2413913T3 (enExample) |
| PT (1) | PT2413913T (enExample) |
| RU (1) | RU2550133C2 (enExample) |
| WO (1) | WO2010114405A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| ES2644049T3 (es) | 2007-01-31 | 2017-11-27 | Bial - Portela & Ca., S.A. | Régimen de dosificación para inhibidores de COMT |
| BRPI0908731A2 (pt) | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
| BRPI1014865B1 (pt) | 2009-04-01 | 2020-03-17 | Bial - Portela & C.A., S.A. | Composição que compreende grânulos compreendendo 2,5- dicloro- 3- (5- (3,4- dihidróxi- 5- nitrofenil)- 1,2,4- oxadiazol- 3- il)- 4,6- dimetilpiridina 1- óxido e formulação farmacêutica |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT3604299T (pt) | 2011-12-13 | 2023-10-31 | Bial Portela & Ca Sa | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| JP2021506762A (ja) * | 2017-12-18 | 2021-02-22 | ユニケム ラボラトリーズ リミテッド | オピカポンとその中間体の製造方法 |
| US12059424B2 (en) * | 2018-03-01 | 2024-08-13 | Astrazeneca Ab | Pharmaceutical compositions comprising (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| WO2020072884A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| CN115335036A (zh) | 2020-03-13 | 2022-11-11 | 巴尔-波特拉及康邦亚股份有限公司 | 微粉化的奥匹卡朋 |
| GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
| GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| KR20230118933A (ko) | 2020-12-17 | 2023-08-14 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 초기 특발성 파킨슨병에 대한 치료 요법 |
| WO2022180649A1 (en) * | 2021-02-26 | 2022-09-01 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
| GB202212082D0 (en) | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| WO2024148308A1 (en) | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| AU2023449890A1 (en) | 2023-05-25 | 2025-11-27 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) * | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4085563A (en) * | 1977-01-31 | 1978-04-25 | Campbell Soup Company | Cookie dispensing apparatus |
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4368668A (en) * | 1981-05-15 | 1983-01-18 | Veb Kombinat Polygraph "Werner Lamberz" Leipzig | Printing plate mounting arrangement |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US6206110B1 (en) * | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| EP1114039A1 (en) * | 1998-09-18 | 2001-07-11 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
| GB2344819A (en) * | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1356046B1 (en) * | 2000-11-28 | 2009-10-14 | ZymoGenetics, L.L.C. | Cytokine receptor zcytor19 |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| WO2002060446A1 (fr) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif |
| MXPA03011196A (es) * | 2001-06-08 | 2004-10-28 | Cytovia Inc | 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos. |
| US7144876B2 (en) * | 2002-12-18 | 2006-12-05 | Cytovia, Inc. | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| EP1673071A1 (en) * | 2003-09-29 | 2006-06-28 | Novo Nordisk Femcare AG | Improved stability of progestogen formulations |
| US7300406B2 (en) * | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| DE602005020611D1 (de) * | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| EP1625849A1 (en) * | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20080051441A1 (en) * | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| US20060257473A1 (en) * | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| MX2007015165A (es) * | 2005-06-03 | 2008-02-14 | Abbott Lab | Derivados de ciclobutil-amina. |
| JP2007024970A (ja) * | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| WO2007013830A1 (en) * | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| US20070048384A1 (en) * | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| JP2008162955A (ja) * | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
| ES2644049T3 (es) * | 2007-01-31 | 2017-11-27 | Bial - Portela & Ca., S.A. | Régimen de dosificación para inhibidores de COMT |
| PE20081891A1 (es) * | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| BRPI0908731A2 (pt) * | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
-
2010
- 2010-03-31 WO PCT/PT2010/000015 patent/WO2010114405A2/en not_active Ceased
- 2010-03-31 BR BRPI1016132A patent/BRPI1016132B8/pt active IP Right Grant
- 2010-03-31 CN CN201080022455.3A patent/CN102438595B/zh active Active
- 2010-03-31 CA CA2757418A patent/CA2757418C/en active Active
- 2010-03-31 KR KR1020117025867A patent/KR101824257B1/ko active Active
- 2010-03-31 DK DK10714386.9T patent/DK2413913T3/da active
- 2010-03-31 JP JP2012503351A patent/JP5864410B2/ja active Active
- 2010-03-31 PL PL10714386.9T patent/PL2413913T3/pl unknown
- 2010-03-31 CN CN201610184873.1A patent/CN105816456A/zh active Pending
- 2010-03-31 US US12/750,957 patent/US20100256194A1/en not_active Abandoned
- 2010-03-31 PT PT107143869T patent/PT2413913T/pt unknown
- 2010-03-31 RU RU2011143619/15A patent/RU2550133C2/ru active IP Right Revival
- 2010-03-31 ES ES10714386T patent/ES2915698T3/es active Active
- 2010-03-31 EP EP10714386.9A patent/EP2413913B1/en active Active
- 2010-03-31 MX MX2011010311A patent/MX361618B/es active IP Right Grant
- 2010-03-31 AU AU2010231962A patent/AU2010231962B2/en active Active
-
2015
- 2015-08-27 JP JP2015168153A patent/JP6336420B2/ja active Active
-
2018
- 2018-09-05 US US16/122,643 patent/US20190008774A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,013 patent/US20210315824A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102438595A (zh) | 2012-05-02 |
| BRPI1016132A2 (pt) | 2016-04-19 |
| JP2012522764A (ja) | 2012-09-27 |
| MX361618B (es) | 2018-12-13 |
| CN105816456A (zh) | 2016-08-03 |
| BRPI1016132B1 (pt) | 2020-11-24 |
| CA2757418A1 (en) | 2010-10-07 |
| WO2010114405A2 (en) | 2010-10-07 |
| EP2413913B1 (en) | 2022-05-18 |
| RU2011143619A (ru) | 2013-05-10 |
| WO2010114405A3 (en) | 2011-01-06 |
| MX2011010311A (es) | 2012-03-07 |
| JP5864410B2 (ja) | 2016-02-17 |
| DK2413913T3 (da) | 2022-06-13 |
| ES2915698T3 (es) | 2022-06-24 |
| RU2550133C2 (ru) | 2015-05-10 |
| KR20120008040A (ko) | 2012-01-25 |
| US20210315824A1 (en) | 2021-10-14 |
| BRPI1016132B8 (pt) | 2021-05-25 |
| CN102438595B (zh) | 2016-04-27 |
| PL2413913T3 (pl) | 2022-09-26 |
| AU2010231962B2 (en) | 2015-05-21 |
| AU2010231962A1 (en) | 2011-11-17 |
| JP2016020369A (ja) | 2016-02-04 |
| KR101824257B1 (ko) | 2018-01-31 |
| EP2413913A2 (en) | 2012-02-08 |
| US20100256194A1 (en) | 2010-10-07 |
| US20190008774A1 (en) | 2019-01-10 |
| CA2757418C (en) | 2021-06-15 |
| JP6336420B2 (ja) | 2018-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2413913T3 (pl) | Formulacje farmaceutyczne zawierające pochodne nitrokatecholu oraz sposoby ich wytwarzania | |
| PT2413912T (pt) | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir | |
| PL3100728T3 (pl) | Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania | |
| IL214822A0 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| IL217912A (en) | History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It | |
| IL199853A (en) | Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them | |
| SG10201912687WA (en) | Stable Pharmaceutical Composition And Methods Of Using Same | |
| ZA200900345B (en) | Preparation of pharmaceutical formulations | |
| IL219120A (en) | Cyclohaphtha pyridinyl derivatives and their use in drug preparation | |
| IL224288A (en) | Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use | |
| IL222751A0 (en) | Pharmaceutical compositions and methods of making same | |
| IL215497A0 (en) | Oxadiazile derivatives and pharmaceutical compositions containing them | |
| IL206594A (en) | The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations | |
| IL219155A0 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| IL214907A (en) | Derivatives of benzothiazines, methods for their preparation and medicinal compounds containing them | |
| EP2320738A4 (en) | SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF | |
| IL205313A0 (en) | Pharmaceutical formulation of clavulanic acid | |
| ZA201108458B (en) | Nitrile derivatives and their pharmaceutical use and compositions | |
| IL214408A0 (en) | Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors | |
| IL224191A (en) | Compositions of vitamin d and cmc epi-14 analogues | |
| IL191922A0 (en) | Pharmaceutical formulations of oxcarbazepine and methods for its preparation | |
| PT2484661T (pt) | Derivado de 2,3-di-hidro-1h-inden-2-il-ureia e sua aplicação farmacêutica | |
| PT2597084T (pt) | Derivado de n-hidroxiformamida e medicamento contendo o mesmo | |
| IL214407A0 (en) | Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl)benzothiazoles and benzoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors | |
| HK1168781A (en) | Nitrile derivatives and their pharmaceutical use and compositions |